Investigating how IL-17 affects cancer growth and treatment resistance
IL-17-driven mechanisms for tumor progression and resistance to therapies
This study is looking at how a protein called IL-17 affects cancer growth and treatment success, aiming to find out why some patients don’t respond well to therapies, so we can discover better ways to help people with cancer.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10910031 on NIH RePORTER |
What this research studies
This research explores the role of interleukin 17A (IL-17) in cancer progression and how it influences the effectiveness of cancer therapies. By examining the interactions between IL-17, cancer cells, and the surrounding tumor environment, the study aims to uncover mechanisms that lead to poor treatment outcomes. The researchers will utilize advanced techniques, including transcriptomic profiling and lineage tracing, to identify specific tumor cell populations that are affected by IL-17 and to understand how these cells develop resistance to chemotherapy and immunotherapy. This work could provide insights into new therapeutic strategies for improving cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors exhibiting high levels of IL-17 and those who have experienced resistance to cancer treatments.
Not a fit: Patients with early-stage cancers that are responsive to standard therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with cancers that are resistant to current therapies.
How similar studies have performed: Other research has shown promising results in understanding the role of inflammatory cytokines like IL-17 in cancer progression, suggesting that this approach could yield valuable insights.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Stappenbeck, Thaddeus S — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Stappenbeck, Thaddeus S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.